
<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <title>Clinical Trials Tables - Full</title>
    <style>
        body { font-family: Arial, sans-serif; margin: 20px; }
        table { border-collapse: collapse; width: 100%; margin-bottom: 20px; }
        th, td { border: 1px solid #999; padding: 8px; text-align: left; }
        th { background-color: #eee; }
        h2 { margin-top: 40px; }
    </style>
</head>
<body>
    <h2>Clinical Trials - UCI</h2>
    <table>
      <thead>
        <tr><th>Disease State</th><th>Study Description</th></tr>
      </thead>
      <tbody>
        <tr>
          <td>Plaque Psoriasis</td>
          <td>
            Oral apremilast for pediatric subjects (ages 6–17) with mild–mod psoriasis (BSA 2–15%), OPEN LABEL. (CCR-23-80)<br>
            Multicentre, randomised, placebo-controlled, double blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy. PG should be 5–80 cm² and present &lt;6 months. The study is IV spesolimab + steroids vs placebo + steroids then crossover so all patients receive med. (CCR-24-119)
          </td>
        </tr>
        <tr>
          <td>Alopecia Areata</td>
          <td>
            SQ dupilumab for mod–severe AA (≥ 50% scalp and IgE &gt; 200 and/or personal and/or familial history of atopy). (CCR-23-139)<br>
            Oral JAKi upadacitinib for severe AA (≥ 50% scalp). (CCR-23-100)
          </td>
        </tr>
        <tr>
          <td>Port Wine Birthmark</td>
          <td>
            Light Dose (Fluence)/Hemoporfin + Green Light PDT for Port-wine birthmarks of face/neck. (CCR-23-18)<br>
            Angiogenesis biopsy study (16 years of age and up) (IIT). (IRB# 20076094)
          </td>
        </tr>
        <tr>
          <td>Nonsegmental Vitiligo</td>
          <td>
            Phototherapy with biopsy. Compensation $100–$200 (IIT). (IRB# 1792)<br>
            Quantitative imaging technique with phototherapy at GHEI (incl 3 biopsies). Compensation up to $570 (IIT). (IRB# 2370)<br>
            Punch grafting for stable lesions (compensation: $100)–IIT (IRB# 1792)
          </td>
        </tr>
        <tr>
          <td>Cutaneous Lupus Erythematosus</td>
          <td>SQ Anifrolumab for DLE/SCLE ± SLE. (CCR-23-74)</td>
        </tr>
        <tr>
          <td>EGFR inhibitor induced acneiform reaction</td>
          <td>Topical Hoth CLEER-001 for EGFR induced acneiform eruption. (UCI23-153)</td>
        </tr>
        <tr>
          <td>Pigmented lesions</td>
          <td>
            Non-invasive imaging modalities for assessment of skin (7 years of age and up) (IIT). (IRB# 20086307)<br>
            Non-invasive imaging with potential biopsies (All ages). Compensation: $50–$300 (IIT). (IRB# 20118494)
          </td>
        </tr>
        <tr>
          <td>Normal Skin</td>
          <td>Non-invasive imaging with OCT. Requires 1.5 hours (IIT). (IRB# 2760)</td>
        </tr>
        <tr>
          <td>Atopic dermatitis/psoriasis/CTCL</td>
          <td>Multiphoton microscopy imaging of immune cells. Ages 18–65. Compensation $100–$500 (IIT). (IRB# 20216791)</td>
        </tr>
        <tr>
          <td>Melanoma</td>
          <td>Multiphoton microscopy imaging to monitor immune activation induced by checkpoint inhibitors. Adults. Compensation $50–$200 (IIT). (IRB# 3654)</td>
        </tr>
        <tr>
          <td>Morphea/scleroderma/EF</td>
          <td>3 mm punch biopsy of any autoimmune sclerosing skin disease. Compensation: $200 (IIT). (IRB# 3273)</td>
        </tr>
        <tr>
          <td>Acne Scarring</td>
          <td>SUPERB ultrasound therapy for acne scarring in skin of color (22 years and older with Fitzpatrick skin types IV–VI). (IIT). (IRB# 5557)</td>
        </tr>
        <tr>
          <td>Microcystic Lymphatic Malformations</td>
          <td>PTX-022 (sirolimus) Topical Gel for ≥ moderate microcystic lymphatic malformations (&gt;~9 cm² and &lt; ~200 cm²) in subjects ≥ 3 years of age at consent, OPEN LABEL. (CCR-25-19)</td>
        </tr>
      </tbody>
    </table>
    <p>For the above trials, please send inquiries or referrals to: <a href="mailto:CCREnrollment@hs.uci.edu">CCREnrollment@hs.uci.edu</a>, (833) 824-7839; IIT studies: <a href="mailto:hhkim3@uci.edu">hhkim3@uci.edu</a>.</p>

    <h2>Clinical Trials - Mission Demratology</h2>
    <table>
      <thead>
        <tr><th>Disease State</th><th>Study Description</th></tr>
      </thead>
      <tbody>
        <tr>
          <td>Atopic Dermatitis</td>
          <td>Non-steroidal topical roflumilast cream for infant subjects (ages ≥ 6 months and &lt; 2 years) with mild–mod atopic dermatitis (BSA ≥ 3%), OPEN LABEL. NO blood draws. Compensation: $200. Recruitment anticipated to open May 2025, enrolling 100 subjects. (NCT # pending)</td>
        </tr>
        <tr>
          <td>Plaque Psoriasis</td>
          <td>Topical tapinarof cream (VTAMA) for pediatric subjects (ages 2–17) with mild–severe plaque psoriasis (BSA ≥ 3%), OPEN LABEL. Compensation up to $1,100. Enrollment opened November 2022; close date extended to July 2025. Enrolling 100 subjects. (NCT05172726)</td>
        </tr>
        <tr>
          <td>Prurigo Nodularis</td>
          <td>SQ dupilumab for pediatric subjects (ages ≥ 6 months and &lt; 18 years) with prurigo nodularis (IGA PN-S score of ≥ 2 with presence of ≥ 6 pruriginous lesions), OPEN LABEL. Compensation: $900. Enrollment opened March 2024; enrolling 18 subjects. (NCT06293053)</td>
        </tr>
        <tr>
          <td>Epidermolysis Bullosa Simplex</td>
          <td>Diacerein ointment for subjects (ages ≥ 6 months) with mod–severe epidermolysis bullosa simplex (BSA ≥ 3%, excluding palms and soles). Includes open-label extension so all patients receive the medication. Compensation: $750. Enrollment opened August 2024; enrolling 80–100 subjects. (NCT06073132)</td>
        </tr>
        <tr>
          <td>Dystrophic Epidermolysis Bullosa</td>
          <td>Intradermal gene therapy for subjects (ages ≥ 18 months) with dystrophic epidermolysis bullosa (2 non-healing or recurrent wounds with approximate minimum area of 5 cm² (if 2–6 years of age) or 10 cm² (if 7 years of age or older)). Every subject receives the medication since paired wounds. Compensation: $2,750. Enrollment opened February 2025; enrolling 32 subjects. (NCT06892639)</td>
        </tr>
        <tr>
          <td>Ophthalmologic gene therapy</td>
          <td>For subjects (ages ≥ 6 months) with corneal abrasions due to dystrophic epidermolysis bullosa. Includes open-label treatment phase so all subjects receive medication. Compensation: $1,100. Enrollment pending.</td>
        </tr>
      </tbody>
    </table>
    <p>For the above trials, please send inquiries or referrals to: <a href="mailto:admin@missiondermatology.com">admin@missiondermatology.com</a>, (949) 858-3376 #107.</p>
</body>
</html>